Literature DB >> 3127114

Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration.

D J Back1, S F Grimmer, S Rogers, P J Stevenson, M L Orme.   

Abstract

The plasma concentrations of levonorgestrel (LNG) and ethinyloestradiol (EE2) have been measured in a random crossover study in five healthy female volunteers given a combination oral contraceptive tablet (250 micrograms LNG and 50 micrograms EE2) by the oral route and per vaginum and also receiving the same dose intravenously. The fractional bioavailability of LNG after oral administration was 1.00 +/- 0.16 (mean +/- S.D.) and after vaginal insertion 0.88 +/- 0.16. The time to peak (tmax) was significantly longer and the peak concentration (Cmax) significantly reduced following vaginal administration. The fractional bioavailability of EE2 after oral dosing was 0.62 +/- 0.11 and after vaginal insertion 0.74 +/- 0.16; tmax was prolonged, hence absorption was slower from the vagina. The reduced rate of absorption was evident in the differences seen in the area under the curve for early time periods for both steroids. However, overall bioavailability is not reduced for either steroid when a single tablet is inserted into the vagina.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3127114     DOI: 10.1016/0010-7824(87)90095-3

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

Review 1.  Clinical pharmacokinetics of contraceptive steroids. An update.

Authors:  G M Shenfield; J M Griffin
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 2.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

3.  Transdermal dual-controlled delivery of contraceptive drugs: formulation development, in vitro and in vivo evaluations, and clinical performance.

Authors:  Y W Chien; T Y Chien; R E Bagdon; Y C Huang; R H Bierman
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

4.  Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial.

Authors:  R Dmitrovic; A R Kunselman; R S Legro
Journal:  Hum Reprod       Date:  2013-08-06       Impact factor: 6.918

Review 5.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

6.  Comparing the effects of low-dose contraceptive pills to control dysfunctional uterine bleeding by oral and vaginal methods.

Authors:  Ferdous Mehrabian; Fariba Abbassi
Journal:  Pak J Med Sci       Date:  2013-09       Impact factor: 1.088

Review 7.  Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology.

Authors:  Stefano Lello; Andrea Cavani
Journal:  Int J Endocrinol       Date:  2014-11-16       Impact factor: 3.257

Review 8.  A systematic review of effectiveness and safety of different regimens of levonorgestrel oral tablets for emergency contraception.

Authors:  Mohammad Shohel; Mohammad Mahfuzur Rahman; Asif Zaman; Mir Muhammad Nasir Uddin; Md Mamun Al-Amin; Hasan Mahmud Reza
Journal:  BMC Womens Health       Date:  2014-04-04       Impact factor: 2.809

9.  Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.

Authors:  Udoamaka Ezuruike; Helen Humphries; Maurice Dickins; Sibylle Neuhoff; Iain Gardner; Karen Rowland Yeo
Journal:  Clin Pharmacol Ther       Date:  2018-04-27       Impact factor: 6.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.